On Tuesday, CytomX Therapeutics Inc (NASDAQ: CTMX) was -1.84% drop from the session before settling in for the closing price of $0.75. A 52-week range for CTMX has been $0.40 – $5.85.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 36.21% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -58.68%. With a float of $78.13 million, this company’s outstanding shares have now reached $80.10 million.
In an organization with 121 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 99.33%, operating margin of 18.1%, and the pretax margin is 23.24%.
CytomX Therapeutics Inc (CTMX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward CytomX Therapeutics Inc stocks. The insider ownership of CytomX Therapeutics Inc is 2.46%, while institutional ownership is 58.59%. The most recent insider transaction that took place on Mar 18 ’25, was worth 22,556. In this transaction CEO of this company sold 37,656 shares at a rate of $0.60, taking the stock ownership to the 995,195 shares. Before that another transaction happened on Mar 18 ’25, when Company’s Chief Financial Officer sold 8,551 for $0.60, making the entire transaction worth $5,122. This insider now owns 201,026 shares in total.
CytomX Therapeutics Inc (CTMX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -58.68% per share during the next fiscal year.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
You can see what CytomX Therapeutics Inc (CTMX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.25. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.39, a number that is poised to hit 0.12 in the next quarter and is forecasted to reach -0.60 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.07 million. That was inferior than the volume of 1.71 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 91.45%. Additionally, its Average True Range was 0.06.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 32.95%, which indicates a significant decrease from 88.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 134.30% in the past 14 days, which was higher than the 88.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6513, while its 200-day Moving Average is $1.0066. However, in the short run, CytomX Therapeutics Inc’s stock first resistance to watch stands at $0.7678. Second resistance stands at $0.7994. The third major resistance level sits at $0.8189. If the price goes on to break the first support level at $0.7167, it is likely to go to the next support level at $0.6972. The third support level lies at $0.6656 if the price breaches the second support level.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
There are 80,100K outstanding shares of the company, which has a market capitalization of 58.96 million. As of now, sales total 138,100 K while income totals 31,870 K. Its latest quarter income was 38,090 K while its last quarter net income were 18,880 K.
